# Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

> **NCT00986414** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 260 (estimated)

## Conditions studied

- Parkinson Disease
- Dyskinesias

## Interventions

- **DRUG:** AFQ056
- **DRUG:** AFQ056
- **DRUG:** AFQ056
- **DRUG:** AFQ056
- **DRUG:** AFQ056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00986414
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986414, "Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00986414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*